Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia.

Gassner, FJ; Weiss, L; Geisberger, R; Hofbauer, JP; Egle, A; Hartmann, TN; Greil, R; Tinhofer, I; Cancer Immunol Immunother. 2011; 60(1):7-85

Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria.

Poeppl, W; Hell, M; Herkner, H; Stoiser, B; Fritsche, G; Schurz-Bamieh, N; Poeppl, G; Gattringer, R; Jones, N; Maass, M; Egle, A; Burgmann, H; Infection. 2011; 39(4):341-352

Current evidence for the treatment of invasive fungal infections in immunocompromised patients

Auberger, J; Lass-Florl, C; Clinical investigation. 2011; 1 (3): 447-457.

Protein Kinase C-beta Dependent Activation of NF-kappa B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in Vivo

Lutzny, G; Kocher, T; Rudelius, M; Schmidt-Supprian, M; Klein-Hitpass, L; Durig, J; Oostendorp, RAJ; Peschel, C; Egle, A; Ringshausen, I BLOOD. 2012; 120(21):

Abstract S4-3: The EndoPredict score identifies late distant metastases in ER+/HER2− breast cancer patients

Dubsky, P; Brase, JC; Fisch, K; Jakesz, R; Singer, CF; Greil, R; Dietze, O; Weber, KE; Petry, C; Kronenwett, R; Rudas, M; Knauer, M; Gnant, M; Filipits, M; Cancer Research. 2012; 72(24 Suppl.):-Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium; 04.-08.12.2012; San Antonio, TX.

Upgraded Cobas TaqMan version 2: hidden consequences at cohort level

Taylor, N; Grabmeier-Pfistershammer, K; Oberkofler, H; Egle, A; Rieger, A; Ledergerber, B J INT AIDS SOC. 2012; 15: 109-109.

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

d’Amore, F; Leppa, S; da Silva, MC; Relander, T; Brown, PD; Weidmann, E; Lauritzsen, GF; Pezzutto, A; Van Hoof, A; van Gelder, M; Doorduijn, JK; Wu, KL; Kluin-Nelemans, JC; Lugtenburg, PJ; Jankovska, M; Merup, M; Fagerli, UM; Walewski, J; Hagberg, H; Mariz, JM; Hansen, PB; Nosslinger, T; Janssens, A; Brandefors, L; Demuynck, H; Schaafsma, MR; Christiansen, I; Salek, D; Jyrkkio, S; Prochazka, V; Zijlstra, J; Bohmer, L; Greil, R; Stevens, W; Fijnheer, R; Kooy, MV; Grube, M; Hopfinger, G; Van den Neste, E; Jantunen, E; Trumper, L; Wulf, G; Altmann, B; Ziepert, M; Loeffler, M; Toldbod, H BLOOD. 2012; 120(21):

AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)

Gisslinger, H; Kralovics, R; Gisslinger, B; Lechner, D; Buxhofer-Ausch, V; Strecker, K; Gastl, G; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Schloegl, E; Tarmann, FJ; Zoerer, M; Klade, C; Zahriychuk, O; Thaler, J BLOOD. 2012; 120(21):

Treatment of Aggressive B-Cell Lymphoma in the Elderly: The Influence of SNPs Affecting Pharmacodynamics Is Different Compared to Younger Patient

Melchardt, T; Weiss, L; Hufnagl, C; Neureiter, D; Kemmerling, R; Morre, P; Boekstegers, A; Hopfinger, G; Greil, R; Egle, A BLOOD. 2012; 120(21):

RITUXIMAB PLUS SUBCUTANEOUS CLADRIBINE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA ASSOCIATED TISSUE (MALT-LYMPHOMA): A PHASE II STUDY BY THE AGMT (ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE)

Troch, M; Kiesewetter, B; Willenbacher, W; Willenbacher, E; Zebisch, A; Linkesch, W; Fridrik, MA; Mullauer, L; Greil, R; Raderer, M ANN ONCOL. 2012; 23: 352-352.